Human Dental Pulp Stem Cells Attenuate Neuroinflammation and Neurological Deficit in a Murine Model of Multiple Sclerosis

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system mediated by autoimmune demyelination. While treatments targeting the peripheral immune system have been effective in reducing relapse risks for MS patients, the neuroinflammation within the central nervous system, which is believed to contribute to neurodegeneration, has not been successfully addressed. Human Dental Pulp Stem Cells (hDPSCs) have shown potential in entering the CNS and exerting anti-inflammatory effects, making them a promising candidate for treating neurological disorders. In experimental autoimmune encephalomyelitis (EAE) models, intravenously administered hDPSCs ameliorated clinical scores, decreased demyelinated lesion volume, and reduced inflammatory infiltration. Given the established safety profile, hDPSCs could potentially be developed as a new approach to combat disease progression of MS by inhibiting compartmentalized neuroinflammation.